Suppr超能文献

意外皮内注射缓释丁丙诺啡后早期切除坏死组织。

Early Surgical Excision of Necrotic Tissue Following Unintentional Dermal Injection of Extended-Release Buprenorphine.

机构信息

From the Department of General Internal Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA (CT, VL, JM, JT, JB); and Grayken Center for Addiction, Boston Medical Center, Boston, MA, Boston, MA (JT).

出版信息

J Addict Med. 2024;18(5):605-607. doi: 10.1097/ADM.0000000000001327. Epub 2024 Jun 11.

Abstract

INTRODUCTION

Extended-release subcutaneous buprenorphine is an increasingly common treatment for opioid use disorder. Serious adverse events are rare and may be poorly understood. This report describes an early surgical intervention to address tissue necrosis resulting from misplaced subcutaneous buprenorphine injection. We review identifying characteristics that distinguish the necrotic reaction from other adverse effects of subcutaneous buprenorphine and offer guidance to continue treatment with subcutaneous buprenorphine.

CASE REPORT

A 33-year-old patient returned to clinic within an hour of his buprenorphine injection, reporting pain and skin changes unlike his previous injections. Non blanching erythema consistent with early necrosis was evident, and the patient was referred for surgical removal of his buprenorphine depot. The patient had uncomplicated healing of the surgical site and was provided sublingual buprenorphine before returning to continue treatment with subcutaneous buprenorphine.

DISCUSSION

Although skin necrosis is known to be a rare complication of subcutaneous buprenorphine injection, early surgical excision to limit injury has not been described. Signs and symptoms of skin necrosis must be better understood to facilitate early intervention and continued treatment.

CONCLUSIONS

This case affirms that a patient may continue treatment with subcutaneous buprenorphine despite suffering skin necrosis and demonstrates the value of early surgical intervention after superficial placement of extended-release buprenorphine.

摘要

简介

皮下缓释丁丙诺啡越来越多地用于治疗阿片类药物使用障碍。严重的不良事件很少见,可能了解不足。本报告描述了一种早期手术干预措施,以解决因皮下丁丙诺啡注射位置不当而导致的组织坏死。我们回顾了鉴别特征,将坏死反应与皮下丁丙诺啡的其他不良反应区分开来,并提供了继续皮下丁丙诺啡治疗的指导。

病例报告

一名 33 岁患者在注射丁丙诺啡后 1 小时内返回诊所,报告疼痛和皮肤变化与以往注射不同。明显出现非苍白性红斑,符合早期坏死,患者被转诊进行皮下丁丙诺啡储存库切除术。患者的手术部位愈合顺利,在返回继续接受皮下丁丙诺啡治疗之前,给予舌下丁丙诺啡。

讨论

虽然皮肤坏死是皮下丁丙诺啡注射的已知罕见并发症,但尚未描述早期手术切除以限制损伤。必须更好地了解皮肤坏死的迹象和症状,以促进早期干预和持续治疗。

结论

本病例证实,尽管发生皮肤坏死,患者仍可继续接受皮下丁丙诺啡治疗,并证明了在皮下缓释丁丙诺啡浅表放置后早期手术干预的价值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验